Last week, drugmaker Eli Lilly announced results from a late-stage diabetes trial showing that its daily GLP-1 pill orforglipron significantly reduced A1C (a measure of blood sugar) and body weight compared with placebo (a sham pill)
[13] [14] The type of surgical procedure significantly influences when it is safe to restart GLP-1 medications
Noom Eyes GLP-1s for Longevity, Not Just Weight Loss The digital health platforms new GLP-1 Rx program pairs microdosed weight-loss drugs with biomarker testing and behavior change to target early metabolic risk For consumers intrigued by the promise of GLP-1 medications but who dont meet the BMI requirements typically tied to prescriptions, the door has largely stayed closed until now
Diabetes Care 38 , 264270 (2015)
[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE
If you have a BMI of 22 or higher, you may be an eligible candidate for the GLP-1 Microdose Protocol
_1755853304_WNo_587d407.webp)
